ProForma 2.0
validated simple linear
KFRNWFSQHFKKFKQKLKNTFA
GATR-3
Aliases: GATR-3
Normalized sequence
KFRNWFSQHFKKFKQKLKNTFA
22 amino acids
Release PepDiana-V1-20260620
36
Activity records
1
Source papers
35
Positive
1
Negative / threshold
Versioned scientific descriptors
No separate physicochemical property was reported in the primary-literature identity record. PepDiana release values are shown as computed properties.
Molecular weight
2859.3333 Da
Molecular formula
C138H204N38O29
Theoretical pI
11.4335
Net charge at pH 7
6.8413
GRAVY
-1.2682
Instability index
5.5955
Aromaticity
0.2727
Topological polar surface area
1149.73 Ų
cLogP
-7.7594
Hydrogen-bond donors
40
Hydrogen-bond acceptors
37
Rotatable bonds
99
Method: PepDiana sequence/structure descriptor pipeline
Tool: Biopython+RDKit · Biopython 1.85; RDKit 2024.09.6
Calculated: 2026-06-20T11:01:38.358971+00:00
Assumptions: ph=7; termini=free N-terminus and free C-terminus for simple linear peptides; stereochemistry=standard L-amino acids; smiles_length_limit=200
ProForma 2.0
validated simple linear
KFRNWFSQHFKKFKQKLKNTFA
HELM 2.0
validated simple linear
PEPTIDE1{K.F.R.N.W.F.S.Q.H.F.K.K.F.K.Q.K.L.K.N.T.F.A}$$$$V2.0
Canonical SMILES
validated
CC(C)CC(NC(=O)C(CCCCN)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(Cc1ccccc1)NC(=O)C(CCCCN)NC(=O)C(CCCCN)NC(=O)C(Cc1ccccc1)NC(=O)C(Cc1c[nH]cn1)NC(=O)C(CCC(N)=O)NC(=O)C(CO)NC(=O)C(Cc1ccccc1)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(CC(N)=O)NC(=O)C(CCCNC(=N)N)NC(=O)C(Cc1ccccc1)NC(=O)C(N)CCCCN)C(=O)NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(Cc1ccccc1)C(=O)NC(C)C(=O)O)C(C)O
Isomeric SMILES
validated
CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](C)C(=O)O)[C@@H](C)O
Paper-level observations
Table 2: GATR-3 MIC against A. baumannii AB5075 is 4 µg/mL.
Table 2: GATR-3 MIC against A. baumannii BAA-1710 is 4 µg/mL.
Table 2: GATR-3 MIC against A. baumannii BAA-1794 is 4 µg/mL.
Table 2: GATR-3 MIC against A. baumannii BAA-1795 is 4 µg/mL.
Table 2: GATR-3 MIC against A. baumannii BAA-1797 is 4 µg/mL.
Table 2: GATR-3 MIC against A. baumannii BAA-1799 is 4 µg/mL.
Table 2: GATR-3 MIC against A. baumannii BAA-1800 is 4 µg/mL.
Table 2: GATR-3 MIC against A. baumannii BAA-1605 is 4 µg/mL.
Table 2: GATR-3 MIC against P. aeruginosa BAA-2110 is 8 µg/mL.
Table 2: GATR-3 MIC against K. pneumoniae BAA-1705 is 8 µg/mL.
Table 2: GATR-3 MIC against E. asburiae BAA-3043 is 32 µg/mL.
Table 2: GATR-3 MIC against E. faecalis 51299 is 64 µg/mL.
Table 2: GATR-3 MIC against MRSA (S. aureus 33592) is 64 µg/mL.
Section 2.2: 'The minimum bactericidal concentration (MBC) was determined to be 4 µg/mL after plating each well which showed no growth in the MIC assay on an agar plate, suggesting that GATR-3 is bactericidal at the MIC.'
Table 3: GATR-3 MBIC50 against A. baumannii BAA-1794 is 0.62 µg/mL (95% CI 0.3 to 1.2).
Table 3: GATR-3 MBIC50 against A. baumannii AB5075 is 9.3 µg/mL (95% CI 0.5 to 179.4).
Table 3: GATR-3 MBIC50 against A. baumannii BAA-1710 is 7.4 µg/mL (95% CI 3 to 18.3).
Table 3: GATR-3 MBIC50 against A. baumannii BAA-1795 is 0.91 µg/mL (95% CI 0.6 to 1.38).
Table 3: GATR-3 MBIC50 against A. baumannii BAA-1797 is 0.18 µg/mL (95% CI 0.11 to 0.28).
Table 3: GATR-3 MBIC50 against A. baumannii BAA-1605 is 21.7 µg/mL (95% CI 4.25 to 110.5).
Table 3: GATR-3 MBIC50 against A. baumannii BAA-1800 is 8.8 µg/mL (95% CI 3.46 to 22.15).
Table 4: GATR-3 MBEC50 against A. baumannii BAA-1794 is 9.6 µg/mL (95% CI 4 to 23).
Table 4: GATR-3 MBEC50 against A. baumannii AB5075 is 4.8 µg/mL (95% CI 2.72 to 8.47).
Table 4: GATR-3 MBEC50 against A. baumannii BAA-1710 is 8 µg/mL.
Table 4: GATR-3 MBEC50 against A. baumannii BAA-1795 is >64 µg/mL.
Table 4: GATR-3 MBEC50 against A. baumannii BAA-1797 is 6 µg/mL (95% CI 2.85 to 12.8).
Table 4: GATR-3 MBEC50 against A. baumannii BAA-1605 is 4.4 µg/mL (95% CI 2.42 to 8).
Table 4: GATR-3 MBEC50 against A. baumannii BAA-1800 is 4.1 µg/mL (95% CI 2.72 to 6.2).
Figure 1A: GATR-3 completely eradicated MDR A. baumannii AB5075 preformed biofilms at 32 µg/mL.
Section 2.9: 'we observed ~50% hemolysis of human blood at 5000 µg/mL (5 mg/mL) GATR-3 peptide. Thus, the HC50 concentration was determined to be 5000 µg/mL.'
Table 5 caption: 'MHC (95% CI) = 595 µg/mL (339–825)'.
Section 2.8.1: 'GATR-3 showed no hemolysis at any of the peptide concentrations tested.' (up to 100 µg/mL).
Section 2.8.2: 'GATR-3 demonstrates 95.8% cell viability at 100 µg/mL.'
Section 2.8.3: 'The GATR-3-treated group demonstrated 90% survival... Each larva was injected with 10 µg of GATR-3 dissolved in 10 µL of PBS (1 mg/mL).'
Table 5: MHC Therapeutic Index (MHC/MIC) for GATR-3 against A. baumannii is 149.
Table 5: HC50 Therapeutic Index (HC50/MIC) for GATR-3 against A. baumannii is 1250.
Citation and release provenance
Cite this identity as PepDiana record PEPDIA-PLP-001456, release PepDiana-V1-20260620. Experimental observations retain their paper, mention, and activity-record identifiers.
Record updated: 2026-06-22T07:14:26.229247+00:00